CAJ | 학술논문

目的：探讨参芪扶正注射液对胃癌术后患者化疗疗效及免疫功能的影响。方法选取60例胃癌术后患者为研究对象，采用随机数字表法分为对照组和观察组，每组30例。对照组给予 FOLFOX 方案化疗。观察组在 FOLFOX 方案化疗的基础上给予参芪扶正注射液。对所有患者化疗前后病灶复发及转移情况、患者生存情况、免疫功能及不良反应发生情况等指标进行观察。结果观察组化疗周期（3．95±0．40）个，高于对照组化疗周期的（3．40±0．30）个，差异有统计学意义（t ＝6．025，P ＜0．01）。观察组无进展生存期（9．0±2．4）个月，长于对照组无进展生存期的（6．6±3．2）个月，差异有统计学意义（t ＝3．286，P ＜0.01）。观察组白细胞减少率为6．67％，低于对照组的26．67％，差异有统计学意义（χ2＝4．320，P ＜0．05）。观察组恶心、呕吐发生率为6．67％，低于对照组的26．67％，差异有统计学意义（χ2＝4．320，P ＜0．05）。观察组 KPS（83．51±15．37）分及 QLQ-C30（82．01±9．45）分，均高于对照组的（74．95±13．42）分、（74．62±13．22）分，差异均有统计学意义（t ＝2．298、2．491，均 P ＜0．05）。化疗后观察组胃癌患者 CD ＋3、CD ＋4、CD ＋4／CD ＋8均高于对照组，且观察组 CD ＋4／CD ＋25比值低于对照组，差异均有统计学意义（均 P ＜0．05）。结论参芪扶正注射液联合 FOLFOX 方案化疗治疗胃癌患者不良反应率低，能有效改善患者的免疫功能。
목적：탐토삼기부정주사액대위암술후환자화료료효급면역공능적영향。방법선취60례위암술후환자위연구대상，채용수궤수자표법분위대조조화관찰조，매조30례。대조조급여 FOLFOX 방안화료。관찰조재 FOLFOX 방안화료적기출상급여삼기부정주사액。대소유환자화료전후병조복발급전이정황、환자생존정황、면역공능급불량반응발생정황등지표진행관찰。결과관찰조화료주기（3．95±0．40）개，고우대조조화료주기적（3．40±0．30）개，차이유통계학의의（t ＝6．025，P ＜0．01）。관찰조무진전생존기（9．0±2．4）개월，장우대조조무진전생존기적（6．6±3．2）개월，차이유통계학의의（t ＝3．286，P ＜0.01）。관찰조백세포감소솔위6．67％，저우대조조적26．67％，차이유통계학의의（χ2＝4．320，P ＜0．05）。관찰조악심、구토발생솔위6．67％，저우대조조적26．67％，차이유통계학의의（χ2＝4．320，P ＜0．05）。관찰조 KPS（83．51±15．37）분급 QLQ-C30（82．01±9．45）분，균고우대조조적（74．95±13．42）분、（74．62±13．22）분，차이균유통계학의의（t ＝2．298、2．491，균 P ＜0．05）。화료후관찰조위암환자 CD ＋3、CD ＋4、CD ＋4／CD ＋8균고우대조조，차관찰조 CD ＋4／CD ＋25비치저우대조조，차이균유통계학의의（균 P ＜0．05）。결론삼기부정주사액연합 FOLFOX 방안화료치료위암환자불량반응솔저，능유효개선환자적면역공능。
Objective To explore the influence of Shenqifuzheng injection on efficacy of chemotherapy and immune function in patients with gastric cancer after surgery.Methods 60 postoperative patients with gastric cancer were selected as the research subjects,and were randomly divided into the control group and observation group by the digital table,30 cases in each group.The control group was given FOLFOX regimen chemotherapy.The observation group received FOLFOX regimen combined with the treatment of Shenqifuzheng injection.The recurrence and metasta-sis,survival,immune function and adverse reactions of the patients were observed and the patients were observed before and after chemotherapy.Results The chemotherapy cycle of the observation group was (3.95 ±0.40),which was significantly higher than (3.40 ±0.30)of the control group,the difference was statistically significant (t =6.025,P <0.01).The progression free survival in the observation group was (9 ±2.4)months,which was significant-ly longer than (6.6 ±3.2)months in the control group,the difference was statistically significant (t =3.286,P <0.01).The reduction rate in the observation group was 6.67%,which was lower than 26.67% in the control group, the difference was statistically significant (χ2 =4.320,P <0.05).The incidence rate of nausea and vomiting in the observation group was 6.67%,which was lower than 26.67% in the control group,the difference was statistically sig-nificant (χ2 =4.320,P <0.05).KPS[(83.51 ±15.37)points]and QLQ -C30[(82.01 ±9.45)points]of the observation group were significantly higher than those in the control group [KPS (74.62 ±13.22)points and QLQ -C30 (74.62 ±13.22)points],the differences were statistically significant (t =2.298,2.491,all P <0.05).After chemotherapy,gastric cancer patients ratio of CD +3 ,CD +4 ,CD +4 /CD +8 in the observation group were higher than those of the control group and the ratio of CD +4 /CD +25 in the observation group was lower than control group,the differences were statistically significant (all P <0.05).Conclusion Shenqifuzheng injection combined with FOLFOX chemo-therapy for gastric cancer patients has low adverse reaction rate,and can effectively improve the immune function.